Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: January Update

Performance overview

Value at beginning of month: $112,858.19

Value at end of month: $121,630.83

Month over month change: +7.77%

Total IRR: 13.24%

Related indices, monthly change

NASDAQ: +7.61%

IVV (iShares Core S&P 500): +6.43%

IBB (iShares NASDAQ Biotechnology Index): +13.09%

MXI (iShares Global Materials): +6.05%

VEGI (iShares MSCI Global Agriculture Producers): +7.57%

ICLN (iShares Clean Energy): +11.30%

Individual performances

g5643.png

The market in January was bouncing back from a disastrous December, so it is no surprise that the index had a good month as well. A number of agricultural companies started the year off strong, as Yield10, AquaBounty, Calyxt, and Arcadia were all up over 20%. During this time period, Yield10 released field trial results demonstrating that their technology was improving yields, which gave the whole agricultural biotechnology industry a boost. Amyris fell the most, even though it signed a new deal to produce an unnamed nutritional product.

Changes made to index

None.

You can view the index here.

Allocation as of February 18, 2019

Calvin Schmidt Synthetic Biology Index: February Update

2018 SynBio Venture Review